Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study

Keyphrases

• Angiotensin Receptor Blockers 100%
• Nationwide Registry 100%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 100%
• Angioedema 100%
• Registry-based Cohort Study 100%
• Adjusted Hazard Ratio 30%
• Antihypertensive Drugs 20%
• Inhibitor Treatment 20%
• Danish Population 10%
• High Risk 10%
• Incidence Rate 10%
• Health Registries 10%
• Cross-reactivity 10%
• Calcium Channel Blockers 10%
• Propensity Score 10%
• Thiazides 10%
• Proportional Hazards Model 10%
• Beta-adrenergic Blockers 10%
• Inverse Association 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Angiotensin Receptor Antagonist 100%
• Cohort Study 100%
• Dipeptidyl Carboxypeptidase Inhibitor 100%
• Angioneurotic Edema 100%
• Antihypertensive Drug 20%
• Antihypertensive 20%
• Beta Adrenergic Receptor Blocking Agent 10%
• Recurrent Disease 10%
• Calcium Channel Blocker 10%
• Thiazide Diuretic Agent 10%